Skip to main content

Table 3 Adverse events by treatment group

From: A randomized, double-blind, placebo-controlled phase II trial to explore the effects of a GABAA-α5 NAM (basmisanil) on intellectual disability associated with Down syndrome

Adverse events (in more than 5% of participants)

Placebo

120 mg (80 mg)

240 mg (160 mg)

n

%

n

%

n

%

Infections and infestations

32

55.2

24

43.6

24

42.1

Gastrointestinal disorders

18

31.0

12

21.8

15

26.3

Nervous system disorders

14

24.1

13

23.6

13

22.8

Investigations

12

20.7

5

9.1

6

10.5

Skin and subcutaneous tissue disorders

8

13.8

6

10.9

6

10.5

Psychiatric disorders

5

8.6

6

10.9

8

14.0

General disorders and administration site conditions

5

8.6

7

12.7

6

10.5

Respiratory, thoracic, and mediastinal disorders

4

6.9

7

12.7

2

3.5

Musculoskeletal and connective tissue disorders

2

3.4

5

9.1

5

8.8

Eye disorders

4

6.9

3

5.5

1

1.8

Injury, poisoning and procedural complications

0

0

4

7.3

3

5.3

Serious adverse events

n

 

n

 

n

 

Suicidal ideation

1

   

1

 

Altered state of consciousness

  

1

   

Skin laceration

  

1

   

Salmonellosis

    

1